BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Atkins AJ, Allen AG, Dampier W, Haddad EK, Nonnemacher MR, Wigdahl B. HIV-1 cure strategies: why CRISPR? Expert Opin Biol Ther 2021;21:781-93. [PMID: 33331178 DOI: 10.1080/14712598.2021.1865302] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Valdebenito S, Ono A, Rong L, Eugenin EA. The role of tunneling nanotubes during early stages of HIV infection and reactivation: implications in HIV cure. NeuroImmune Pharmacology and Therapeutics 2023;0. [DOI: 10.1515/nipt-2022-0015] [Reference Citation Analysis]
2 Chen J, Zhou T, Zhang Y, Luo S, Chen H, Chen D, Li C, Li W. The reservoir of latent HIV. Front Cell Infect Microbiol 2022;12:945956. [DOI: 10.3389/fcimb.2022.945956] [Reference Citation Analysis]
3 Kuniholm J, Coote C, Henderson AJ. Defective HIV-1 genomes and their potential impact on HIV pathogenesis. Retrovirology 2022;19:13. [PMID: 35764966 DOI: 10.1186/s12977-022-00601-8] [Reference Citation Analysis]
4 Dampier W, Link RW, Earl JP, Collins M, De Souza DR, Koser K, Nonnemacher MR, Wigdahl B. HIV- Bidirectional Encoder Representations From Transformers: A Set of Pretrained Transformers for Accelerating HIV Deep Learning Tasks. Front Virol 2022;2. [DOI: 10.3389/fviro.2022.880618] [Reference Citation Analysis]
5 Liu Y, Jeeninga RE, Klaver B, Berkhout B, Das AT. Transient CRISPR-Cas Treatment Can Prevent Reactivation of HIV-1 Replication in a Latently Infected T-Cell Line. Viruses 2021;13:2461. [PMID: 34960730 DOI: 10.3390/v13122461] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Kanazawa J, Gianella S, Concha-Garcia S, Taylor J, Kaytes A, Christensen C, Patel H, Ndukwe S, Rawlings S, Hendrickx S, Little S, Brown B, Smith D, Dubé K. Ethical and practical considerations for interventional HIV cure-related research at the end-of-life: A qualitative study with key stakeholders in the United States. PLoS One 2021;16:e0254148. [PMID: 34270612 DOI: 10.1371/journal.pone.0254148] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Wang X, Xu H. Residual Proviral Reservoirs: A High Risk for HIV Persistence and Driving Forces for Viral Rebound after Analytical Treatment Interruption. Viruses 2021;13:335. [PMID: 33670027 DOI: 10.3390/v13020335] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]